Previous 10 | Next 10 |
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST CHESTER, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals I...
Verrica Pharmaceuticals (NASDAQ:VRCA): Q3 GAAP EPS of -$0.47 beats by $0.01. Cash, cash equivalents and marketable securities of $79.5M. Press Release For further details see: Verrica Pharmaceuticals EPS beats by $0.01
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum ...
Investors had a hard time making sizable bets on U.S. equities Tuesday in the wake of Monday's sharp sell-off. However, there was some action in one select sector: online gambling and sports betting. A $20B takeover offer in the sector gave a boost to select gambling stocks. Flutter Entertain...
Gainers: Helbiz (NASDAQ:HLBZ) +128%. NanoViricides (NYSE:NNVC) +100%. ReWalk Robotics (NASDAQ:RWLK) +56%. Spire (NYSE:SPIR) +30%. Corvus (NASDAQ:CRVS) +29%. Inotiv (NASDAQ:NOTV) +26%. Candel (NASDAQ:CADL) +23%. Rockley (NYSE:RKLY) +19%. Protagonist (NASDAQ:PTGX) +18%. indie Semiconductor (NAS...
Shares of Verrica Pharmaceuticals (NASDAQ: VRCA) , a clinical-stage biopharmaceutical company, are tumbling after the company disclosed a complete response letter for VP-102. Investors unhappy with the delay pushed the stock 23.4% lower this morning but the stock has recovered a...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +36%, NanoViricides (NYSE:NNVC) +36%, Inotiv (NASDAQ:NOTV) +27%, Solid Biosciences (NASDAQ:SLDB) +22%, eFFECTOR Therapeutics (NASDAQ:EFTR) +16%. Losers: Edesa Biotech (NASDAQ:EDSA) -25%, Verrica Pharmaceuticals (NASDAQ:...
Verrica Pharmaceuticals (NASDAQ:VRCA) -25% after FDA declines to approve VP-102 Edesa Biotech (NASDAQ:EDSA) -19%. ZIVO Bioscience (NASDAQ:ZIVO) -12%. Innate Pharma (NASDAQ:IPHA) -8%. Sentage (NASDAQ:SNTG) -8%. Corvus Pharmaceuticals (NASDAQ:CRVS) -7%. For further details see: ...
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to VP-102 Identified WEST CHESTER, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Verr...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...